Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-05-20 Investor Presentation
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 80% confidence The document is a notice of an upcoming corporate investor relations presentation (IR) on May 26, 2026, detailing event date, time, online link, agenda (Q1 results review, business outlook, Q&A), and where IR materials will be posted. It is not the presentation itself or a full financial report, but an event announcement for investors. This corresponds to the Investor Presentation category.
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Korean for Quarterly Report) for the period 2026.01.01–2026.03.31, includes comprehensive financial data, segment revenue tables, business descriptions, production statistics, and detailed notes. It is not a brief announcement or press release but a full interim/quarterly filing submitted to the Financial Services Commission and Korea Exchange. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official results of the 2026 annual general meeting (정기주주총회 결과), detailing the approval of financial statements, board member reappointments, and vote tallies. It is a declaration of voting results from a shareholder meeting, matching the category for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-23 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a regulatory filing to the Financial Services Commission/Korea Exchange reporting the appointment and reappointment of outside directors (‘사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고’). It details board composition changes and the new outside directors’ profiles. This clearly falls under announcements of changes in the company’s board of directors or senior management. Therefore, it is classified as Board/Management Information (MANG).
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Optipharm. It provides the audit opinion, key financial data, and details regarding the audit process for the fiscal year ending 2025-12-31. While it contains financial data, it is a standalone regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a simple announcement of a report (RPA). It fits the definition of an Audit Report/Information (AR) as it provides the audit opinion and specific financial results verified by an external auditor. FY 2025
2026-03-13 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Optipharm' (주식회사 옵티팜) for the fiscal year ending December 31, 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a report publication announcement. FY 2025
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.